Unlocking Cytokine Detection: Pre-Conjugated Antibody Pairs for Critical Research
Detecting cytokines at ultra-low levels is essential for understanding immune response, inflammation, and disease progression. However, for many researchers, the reliable detection of low-abundance targets, such as IL-4, IL-6, and TNF-α, remains challenging with standard methods.
Cavidi’s new pre-conjugated antibody pair kits change that equation. Optimized for Cavidi's BOLD-enabled Exazym® platform, these kits deliver ultrasensitive detection without specialized equipment or workflow changes, while dramatically simplifying assay development.
IL-6: The Inflammation Sentinel IL-6 serves as a critical biomarker in COVID-19, sepsis, and autoimmune diseases. Yet standard ELISA methods often struggle with clinically relevant concentrations. Cavidi's IL-6 Antibody Pair Kit delivers high sensitivity and reproducibility, making it easier to track subtle immune responses in infection models, drug trials, and patient samples where every picogram matters.
IL-4: Unlocking Allergy and Immunotherapy Research IL-4 drives Th2-mediated immune responses and serves as a key biomarker in asthma, allergy, and immunotherapy research. Cavidi recently demonstrated 50X sensitivity improvement using their IL-4 pair with Exazym, pushing detection well into the femtogram-per-milliliter range. This breakthrough opens new possibilities for studying early allergic responses and therapeutic interventions.
TNF-α: Precision for Autoimmunity and Oncology TNF-α regulates inflammation, autoimmune pathology, and tumor microenvironment dynamics - making it indispensable for therapeutic monitoring and disease progression studies. Cavidi's TNF-α Antibody Pair Kit enables ultra-low-level detection critical for capturing transient or low-grade inflammatory responses that standard assays miss.
Why Pre-Conjugated Matters
Time is precious in research. Cavidi's pre-conjugated pairs eliminate days of optimization work and reduce variability - they’re ready to run with Exazym® for ultrasensitive detection with minimal startup time.
Whether you’re validating therapeutic targets, tracking disease progression, or pushing assay performance limits, these kits offer a fast, reliable, scalable solution.
The Bottom Line: Don’t let sensitivity constraints limit your cytokine research. Let Exazym® do the heavy lifting - so you can focus on the science.
Supplier
Cavidi
Cavidi is a Swedish biotechnology company specialising in ultra-sensitive biomarker detection. Their innovative reagent, Exazym®™, enhances standard ELISA workflows by enabling attomole-level detection of low-abundance biomarkers with minimal adjustments and no need for new equipment.